A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip Pravin Patel(University of San Diego), Razelle Kurzrock(Medical College of Wisconsin), Anup Kasi(University of Kansas Medical Center), Edward Mayerson(Cancer Research And Biostatistics), Elad Sharon(National Cancer Institute), Megan Othus(Cancer Research And Biostatistics), Manisha H. Shah(Centre for Eye Research Australia), Charles D. Blanke(Oregon Health & Science University), Zoran Gatalica(Caris Life Sciences (United States)), Annette Campbell Fontaine(New Mexico Cancer Center), W. Michael Korn(University of California, San Francisco), Melissa Plets(Cancer Research And Biostatistics), Christopher W. Ryan(Oregon Health & Science University), Marc Matrana(Ochsner Medical Center), Francis J. Giles(Northwestern University), Tareq Al Baghdadi(IHA Hematology Oncology Consultants), Preet Paul Singh, Young Kwang Chae(Johns Hopkins University), Christine M. McLeod(SWOG Cancer Research Network), Jourdain Hayward(SWOG Cancer Research Network), Helen X. Chen(National Cancer Institute), Donna E. Hansel(Cleveland Clinic)
Cited by 326
Related Papers
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k